Interferon-alfa kan förbättra prognosen vid högriskmelanom. Kombination kirurgi, cytostatika och naturligt IFN-alfa dubblade överlevnadsfrekvens
Engelsk titel: Interferon-alpha can improve the prognosis in high-risk melanoma. Combination of surgery, cytostatics and natural IFN-alpha doubled the survival rate
Läs online
Författare:
Strannegård Ö
;
Thoren F
;
Lundgren E
Email: orjan.strannegard@microbio.gu.se
Språk: Swe
Antal referenser: 17
Dokumenttyp:
Översikt
UI-nummer: 08021341
Sammanfattning
Interferon-alfa (IFN) can delay the progression of disease if given as adjuvant therapy to patients with high-risk melanoma but this effect has previously not been reported to be associated with a reduction of mortality. Adjuvant IFN therapy is asssociated with increased chance of survival in patients who develop autoimmune manifestations during the course of therapy, suggesting that strong activation of the immune system is a prerequisite for the success of treatment. In a long-term study of treatment with a cytostatic drug, dacarbazine, followed by treatment with natural IFN, that has a variety of immunological effects and is known not to cause therapy resistance, a remarkable reduction of mortality was obtained.